Breaking News

Janssen R&D, MMRF In Personalized Medicine Pact

June 21, 2013

To discover and develop new approaches to treating multiple myeloma

Janssen R&D, LLC has joined the Multiple Myeloma Research Foundation (MMRF) pre-competitive consortium (PCC) to discover and develop new approaches to treating multiple myeloma through the organization’s Personalized Medicine Initiative (PMI). This initiative includes CoMMpass Study (Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile) that collects comprehensive clinical information and molecular profiles of 1,000 newly diagnosed patients for a minimum of five years. Data collected provides researchers with insights needed to more completely characterize the genetic subtypes of multiple myeloma based on responsiveness to specific treatment regimens, with the goal of enabling individualized treatment options.
 
Members of the PCC provide scientific and financial support for the PMI. This collaborative partnership structure provides researchers access to the findings from CoMMpass to accelerate drug discovery and development efforts in multiple myeloma and potentially other cancers.
 
“Our partnership with the oncology industry’s leaders will help to drive scientific and clinical innovation through new models of collaboration,” said Walter M. Capone, chief operating officer of the MMRF. “We are deeply gratified to have Janssen R&D join this breakthrough initiative, and sincerely appreciate all the members of the PCC for their vision, commitment, and support of our mission to accelerate the translation of research findings into therapeutic advancements for patients.”

Related Contract Manufacturing:

blog comments powered by Disqus
  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Major Regulatory Changes in China to Impact Western Drug Developers

    Major Regulatory Changes in China to Impact Western Drug Developers

    David Deere, PaizaBio||January 28, 2016
    PaizaBio reports on drug development and manufacturing strategies

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.